-
Thematic Analysis
NewWeb3 – Thematic Intelligence
Web3 Thematic Report Overview Web3 is an ideology that refers to the next model of the internet built on blockchain. It promises a mix of peer-to-peer (P2P) communication channels and decentralized governance. This will lead the internet’s transition from an information-centric model to a user-centric model. Furthermore, Web3 aims to give users the ability to create, own, and monetize their content and manage the use of their data. However, it is still an emerging model and has a long way...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PXS-4728 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PXS-4728 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PXS-4728 in Parkinson's Disease Drug Details: BI-1467335 (PXS-4728) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PXS-4728 in Sleep Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PXS-4728 in Sleep Disorders report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PXS-4728 in Sleep Disorders Drug Details: BI-1467335 (PXS-4728) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Isuzinaxib in Acute Renal Failure (ARF) (Acute Kidney Injury)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Isuzinaxib in Acute Renal Failure (ARF) (Acute Kidney Injury) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Isuzinaxib in Acute Renal Failure (ARF) (Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vonafexor in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vonafexor in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vonafexor in Chronic Kidney Disease (Chronic Renal Failure)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Narmafotinib in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Narmafotinib in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Narmafotinib in Pancreatic Cancer Drug Details: AMP-945 (CTX-0294945) is under investigation for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MBK-001 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MBK-001 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MBK-001 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: MBK-001 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CS-0159 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CS-0159 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CS-0159 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: CS-0159 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TERN-501 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TERN-501 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TERN-501 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: TERN-501 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ecnoglutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ecnoglutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ecnoglutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: XW-003 is...